Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

253 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Ignatiadis M, Polyzos A, Stathopoulos GP, Tselepatiotis E, Christophylakis C, Kalbakis K, Vamvakas L, Kotsakis A, Potamianou A, Georgoulias V. Ignatiadis M, et al. Among authors: polyzos a. Oncology. 2006;71(3-4):159-63. doi: 10.1159/000106064. Epub 2007 Jul 17. Oncology. 2006. PMID: 17646699 Clinical Trial.
Chemotherapy with gemcitabine, cisplatin, and docetaxel in the treatment for patients with muscle-invasive bladder cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG).
Boukovinas I, Androulakis N, Kentepozidis N, Polyzos A, Papakotoulas P, Ziras N, Kotsakis A, Vardakis N, Karampeazis A, Markos V, Kostakopoulos A, Constantinides CA, Samonis G, Mavroudis D, Georgoulias V. Boukovinas I, et al. Among authors: polyzos a. Cancer Chemother Pharmacol. 2012 Feb;69(2):351-6. doi: 10.1007/s00280-011-1694-9. Epub 2011 Jul 12. Cancer Chemother Pharmacol. 2012. PMID: 21748359 Clinical Trial.
Front-line treatment of inoperable or metastatic pancreatic cancer with gemcitabine and capecitabine: an intergroup, multicenter, phase II study.
Stathopoulos GP, Syrigos K, Polyzos A, Fountzilas G, Rigatos SK, Ziras N, Potamiannou A, Tsiakopoulos I, Androulakis N, Aravantinos G, Athanasiadis A, Papakotoulas P, Georgoulias V. Stathopoulos GP, et al. Among authors: polyzos a. Ann Oncol. 2004 Feb;15(2):224-9. doi: 10.1093/annonc/mdh065. Ann Oncol. 2004. PMID: 14760113 Free article. Clinical Trial.
Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial.
Souglakos J, Syrigos K, Potamianou A, Polyzos A, Boukovinas I, Androulakis N, Kouroussis Ch, Vardakis N, Christophilakis Ch, Kotsakis A, Georgoulias V. Souglakos J, et al. Among authors: polyzos a. Ann Oncol. 2004 Aug;15(8):1204-9. doi: 10.1093/annonc/mdh312. Ann Oncol. 2004. PMID: 15277259 Free article. Clinical Trial.
Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: a multicenter phase II study.
Mavroudis D, Malamos N, Polyzos A, Kouroussis Ch, Christophilakis Ch, Varthalitis I, Androulakis N, Kalbakis K, Milaki G, Georgoulias V; Breast Cancer Study Group of the Hellenic Oncology Research Group (HORG). Mavroudis D, et al. Among authors: polyzos a. Oncology. 2004;67(3-4):250-6. doi: 10.1159/000081325. Oncology. 2004. PMID: 15557786 Clinical Trial.
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
Souglakos J, Androulakis N, Syrigos K, Polyzos A, Ziras N, Athanasiadis A, Kakolyris S, Tsousis S, Kouroussis Ch, Vamvakas L, Kalykaki A, Samonis G, Mavroudis D, Georgoulias V. Souglakos J, et al. Among authors: polyzos a. Br J Cancer. 2006 Mar 27;94(6):798-805. doi: 10.1038/sj.bjc.6603011. Br J Cancer. 2006. PMID: 16508637 Free PMC article. Clinical Trial.
A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer.
Stathopoulos GP, Syrigos K, Aravantinos G, Polyzos A, Papakotoulas P, Fountzilas G, Potamianou A, Ziras N, Boukovinas J, Varthalitis J, Androulakis N, Kotsakis A, Samonis G, Georgoulias V. Stathopoulos GP, et al. Among authors: polyzos a. Br J Cancer. 2006 Sep 4;95(5):587-92. doi: 10.1038/sj.bjc.6603301. Epub 2006 Aug 8. Br J Cancer. 2006. PMID: 16909140 Free PMC article. Clinical Trial.
Sequential gemcitabine and cisplatin followed by docetaxel as first-line treatment of advanced urothelial carcinoma: a multicenter phase II study of the Hellenic Oncology Research Group.
Boukovinas I, Androulakis N, Vamvakas L, Papakotoulas P, Ziras N, Polyzos A, Kalykaki A, Kotsakis A, Xenidis N, Gioulmbasanis I, Mavroudis D, Georgoulias V. Boukovinas I, et al. Among authors: polyzos a. Ann Oncol. 2006 Nov;17(11):1687-92. doi: 10.1093/annonc/mdl286. Epub 2006 Sep 12. Ann Oncol. 2006. PMID: 16968872 Free article. Clinical Trial.
253 results